May 8, 2020 / 12:32 PM / 21 days ago

BRIEF-Meridian Bioscience Reports Second Quarter 2020 Operating Results Raises Guidance On Strength Of Covid-19 Related Products

May 8 (Reuters) - Meridian Bioscience Inc:

* MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2020 OPERATING RESULTS; RAISES GUIDANCE ON STRENGTH OF COVID-19 RELATED PRODUCTS

* RAISING FISCAL 2020 GUIDANCE

* SEES 2020 CONSOLIDATED NET REVENUES $230 MILLION TO $236 MILLION

* QTRLY ADJUSTED EARNINGS PER SHARE $0.23

* SEES 2020 LIFE SCIENCE NET REVENUE $110 MILLION - $114 MILLION

* SEES 2020 ADJUSTED EPS $0.70 TO $0.75

* MERIDIAN BIOSCIENCE - 2020 GUIDANCE CONSIDERS THAT SPENDING ON CLINICAL TRIALS IN FISCAL 2020 WILL BE LOWER THAN ORIGINALLY ANTICIPATED

* MERIDIAN BIOSCIENCE - COVID-19 PANDEMIC HAS PAUSED MOST OF CLINICAL TRIAL SITES, AFFECTED ABILITY TO COLLECT PATIENT SPECIMENS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below